This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pharmacyclics Management Discusses Q4 2012 Results - Earnings Call Transcript

Pharmacyclics (PCYC)

Q4 2012 Earnings Call

September 06, 2012 4:30 pm ET


Rainer M. Erdtmann - Principal Accounting Officer, Vice President of Finance & Administration and Secretary

Robert W. Duggan - Chairman and Chief Executive Officer

Mahkam Zanganeh - Chief Operating Officer

Jesse Seton McGreivy - Vice President of Clinical Science

Joseph J. Buggy - Vice President of Research


Michael J. Yee - RBC Capital Markets, LLC, Research Division

Brian Skorney - Brean Murray, Carret & Co., LLC, Research Division

Alan Carr - Needham & Company, LLC, Research Division

Michael G. King - Rodman & Renshaw, LLC, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division

Joshua Schimmer - Lazard Capital Markets LLC, Research Division

Brian Lian - SunTrust Robinson Humphrey, Inc., Research Division



Greetings, and welcome to the Pharmacyclics Fourth Quarter and Fiscal Year End 2012 Conference Call. [Operator Instructions] A brief question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ramses Erdtmann, Vice President, Finance for Pharmacyclics. Thank you. Mr. Erdmann, you may begin.

Rainer M. Erdtmann

Yes. Thank you, Robin. Good afternoon, and thank you for joining us for our conference call today. With me on the call today and available to answer questions are our CEO and Chairman of the Board, Bob Duggan; our Chief Operating Officer, Dr. Maky Zanganeh; our Executive Vice President, Paula Boultbee; our Executive Vice President of Finance, Josh Brumm; Dr. Jesse McGreivy, our Vice President of Clinical Science; Dr. Maria Fardis, our Vice President of Alliance and Global Project Management; and our Vice President of Research, Dr. Joe Buggy.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.29 0.32%
FB $102.58 3.10%
GOOG $689.75 1.70%
TSLA $148.78 0.36%
YHOO $27.40 2.20%


Chart of I:DJI
DOW 16,065.81 +51.43 0.32%
S&P 500 1,862.71 +10.50 0.57%
NASDAQ 4,314.62 +45.8570 1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs